Catalyst
Slingshot members are tracking this event:
Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer data to be released April - May 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FGEN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 03, 2018
Occurred Source:
https://www.globenewswire.com/news-release/2018/06/04/1515871/0/en/FibroGen-Presents-Clinical-Results-of-Pamrevlumab-Treatment-in-Patients-with-Locally-Advanced-Unresectable-Pancreatic-Cancer-at-ASCO-2018-Annual-Meeting.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Gemcitabine, Nab-paclitaxel, Fg-3019, Unresectable Pancreatic Cancer
